|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Since colon cancers are heterogeneously differentiated, we set out to determine if the GRPR gene was mutated as a function of tumor cell differentiation in archived human colon cancers.
|
12720295 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The current study aimed to develop clinically translatable BBN analogue‑based radioligands for positron emission tomography (PET) of GRPR‑positive tumors.
|
25586565 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Preliminary in vivo studies of 64Cu-6 in NMRI nu/nu mice, bearing the human prostate tumor PC-3 showed an accumulation of the conjugate in the tumor (2.25 +/- 0.13 SUV, 12.5 min p.i.; 0.94 +/- 0.05 SUV, 55 min p.i.) and allowed a clear visualization of the gastrin-releasing peptide receptor distribution by positron emission tomography (PET).
|
19173600 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, the in vivo results confirmed that the blood clearance of the nanoprobe happened during the first 120 min post-injection of the radiolabeled nanoprobe and also confirmed the targeting ability of that to a gastrin-releasing peptide receptor positive tumor.
|
31519003 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study indicates that GRPR and NMBR are widely distributed in human ovarian carcinomas with BRS-3 being found in Stage IV tumors.
|
10828496 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the current study was to develop a <sup>55</sup>Co-labeled PET agent based on GRPR antagonist RM26 for visualization of GRPR-expressing tumors.
|
29097932 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, we describe here the first examples of HBPLs being able to address the GRPR as well as the VPAC<sub>1</sub>R and have the potential to - by several mechanisms - improve tumor targeting for several malignancies compared to monospecific peptides.
|
29864700 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we assessed how the presence of gastrin-releasing peptide receptor (GRPR) and α<sub>v</sub>β<sub>3</sub> integrin together with the morphology of the vascularization reflects the growth behavior of tumors after hyperthermia treatment.
|
28761146 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using PC-3 tumor-bearing xenograft mice, it was observed that the CC trapping, GRPR-targeted agonistic and antagonistic constructs led to an approximately 2-fold increase in tumor retention with a corresponding improvement in most T/NT ratios over 72h.
|
31601697 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant inverse correlations were found for GRPR and increasing Gleason score, PSA value, and tumor size.
|
21739464 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell treatment including gastrin-releasing peptide receptor antagonists combined with inhibition of epidermal growth factor receptor resulted in an additive effect on blocking cell proliferation.
|
19115523 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We herein compare the impact of the two methods on the bioavailability and localization of <sup>177</sup>Lu-DOTA-PEG<sub>4</sub>-[Nle<sup>14</sup>]BBN(7-14) analogs in GRPR-positive tumors in mice.
|
28636973 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrates that (64)Cu-DOTA-Aoc-BN(7-14) can be used to detect GRPR-positive tumors by PET imaging.
|
12862428 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.
|
9815798 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We sought to evaluate the tumor binding and imaging potential of (177)Lu-AMBA in low GRP-R models of prostate cancer and determine how reduced expression affects (177)Lu-AMBA radiotherapy efficacy.
|
19910427 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In short, this study has revealed superior pharmacokinetics and higher stability for the GRPR-antagonist <sup>111</sup> In-SB9 vs the corresponding agonist <sup>111</sup> In-AMBA consolidating previous evidence that GRPR antagonists are preferable to agonists for tumor imaging and therapy.
|
30963606 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bombesin receptor 2 (BB<sub>2</sub>) and integrin α<sub>v</sub>β<sub>3</sub> receptor are privileged targets for molecular imaging of cancer because of their overexpression in a number of tumor tissues.
|
29587479 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells.
|
10037188 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GRPR immunohistochemical staining of tumor samples was performed.
|
29123014 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although GRP is known to have a variety of biological functions, only limited information is available concerning expression of proGRP mRNA and protein, and that of the receptor for GRP (GRPR) in SCLC tumors.
|
12474049 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lu-iPSMA-BN (radiochemical purity>98%) showed specific recognition for PSMA and GRPr (IC50=5.62 and 3.49 nmol/l, respectively) with a significant decrease in cell viability (10.15% of cell viability in LNCaP and 40.10% in PC3 at 48 h), as well as high LNCaP and PC3 tumor uptake (5.21 and 3.21% ID/g at 96 h, respectively).
|
30763290 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a dual isotope biodistribution study, tumor perfusion was accessed using [<sup>99m</sup>Tc]NaTcO<sub>4</sub> and BB2r-targeted uptake evaluated by utilization of a novel <sup>177</sup>Lu-labeled conjugate ([<sup>177</sup>Lu]Lu-DOTA-SP714).
|
31366895 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RT-PCR analyses revealed that the expression of mRNA for receptors of GRP (GRPR/BRS-1) and Neuromedin B (NMBR/BRS-2) on tumors was significantly decreased in all the treated groups.
|
11485826 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The advantages of the RGD-BBN radiotracers over the corresponding BBN analogues are obvious for imaging MDA-MB-435 (GRPR(-)/integrin alpha(v)beta(3)(+)) tumor.
|
20540537 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Results:</b> GRPR overexpression was found in 75.8% of the 1,432 tumors and was most strongly associated with estrogen receptor (ER) positivity (GRPR was high in 83.2% of ER-positive and 12% of ER-negative tumors; <i>P</i> < 0.00001).
|
28280221 |
2017 |